Engineering Synthetic Immunity to Cancer and Beyond
Recorded On: 07/11/2018
- Non-member - Free!
- Full - Free!
- Student - Free!
- SRL Junior Staff - Free!
- SRL Emerging Leader - Free!
- Scholar - Free!
- Emeritus - Free!
- Life - Free!
- ISAC Staff - Free!
- Community Administrator - Free!
- Student Non-Member - Free!
- SRL Junior Staff Non-member - Free!
- Innovator - Free!
About the Presenter
Michael Milone, PhD
Associate Professor of Pathology and Laboratory Medicine
Associate Director, Toxicology Laboratory
University of Pennsylvania Perelman School of Medicine
Dr. Michael Milone received his MD and PhD in experimental pathology in 1999 from New Jersey Medical School. After an internship in internal medicine and post-graduate medical training in clinical pathology and transfusion medicine at the Hospital of the University of Pennsylvania, he pursued a post-doctoral research fellowship with Dr. Carl June at the University of Pennsylvania, where he studied T cell immunotherapy for cancer and designed the CD19-specific CAR-T cell therapy that became CTL019 (tisagenlecleucel, KymriahTM), the first FDA-approved gene therapy in the US. He is a founding member of the Center for Cellular Immunotherapies at the University of Pennsylvania. He currently directs a research laboratory focused on basic and translational immunology that includes the design and application of synthetic immunoreceptors for adoptive cellular therapy of cancer and antibody-mediated disease.
This webinar will provide an overview of engineered T cell adoptive immunotherapies that utilize synthetic immunoreceptors termed chimeric antigen receptors (CARs). Topics to be covered include the design of CAR-T cells, approaches to preclinical assessment of efficacy and toxicity, and the clinical application of this technology to the treatment of malignant and autoimmune disease.
- Understand the design and mechanism of action of engineered T cell adoptive immunotherapies using chimeric antigen receptors (CARs).
- Describe some of the challenges to applying CAR-T cell therapy to cancer therapy.
- Discuss the clinical application of engineered T cells.
Who Should Attend
Scientists, physicians, or technologists with an interest in immunotherapy.
CMLE Credit: 1.0